Charles River Laboratories CRL Impairment Charges
Impairment Charges at other companies
Other financials
Where this comes from
Reported directly by Charles River Laboratories in its filing.
Tagged under the XBRL concept us-gaap:ImpairmentOfLongLivedAssetsHeldForUse.
The official record: Charles River Laboratories’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Charles River Laboratories's impairment charges.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Charles River Laboratories's impairment charges?
- Charles River Laboratories (CRL) reported impairment charges of $15.86M in Q1 2026.
- How has Charles River Laboratories's impairment charges changed year-over-year?
- Charles River Laboratories's impairment charges increased by 50.0% year-over-year, from $10.58M to $15.86M.
- What is the long-term trend for Charles River Laboratories's impairment charges?
- Over 2 years (2023 to 2025), Charles River Laboratories's impairment charges has grown at a 148.6% compound annual growth rate (CAGR), from $41.92M to $259.08M.
- What does impairment charges mean?
- A non-cash expense recorded when an asset's value drops below its book value.
- How do you interpret impairment charges?
- Frequent or large impairment charges signal poor capital allocation, declining asset utility, or deteriorating market conditions.
- How does impairment charges compare across companies?
- Common in industries with high asset turnover or cyclical demand.